• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Saturday, April 1, 2023
Hays County News Online
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

U.S. FDA Declines To Approve Gilead’s HIV Drug On Glass Vial Concerns – Reuters

us.-fda-declines-to-approve-gilead’s-hiv-drug-on-glass-vial-concerns-–-reuters
Share on FacebookShare on Twitter

The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

Register now for FREE unlimited access to Reuters.com

March 1 (Reuters) – The U.S health regulator has declined to approve Gilead Sciences’ (GILD.O) injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on Tuesday.

In a so-called complete response letter, the U.S. Food and Drug Administration (FDA) cited issues related to the compatibility of the drug, lenacapavir, with the proposed borosilicate vial.

“Gilead intends to provide FDA with a comprehensive plan and corresponding data to use a different vial type,” said Merdad Parsey, chief medical officer of Gilead in a statement.

Register now for FREE unlimited access to Reuters.com

Gilead, which is also developing the drug for prevention of HIV-1 infection, plans to discuss the concerns with the agency over the coming months to work towards the drug’s approval.

The issue of compatibility of the vials has been an issue since December, when some of the drug’s trials, including those for prevention of HIV-1, were placed on hold by the FDA due to the potential of formation of sub-visible glass particles in the solution of lenacapavir. (https://bit.ly/3hfeXwc)

The pause was only for injectable lenacapavir. Dosing of oral formulations was allowed to continue.

Gilead’s lenacapavir, meant to be injected under the skin once every six months, was developed for the treatment of patients who have undergone prior therapy and are resistant to multiple existing drugs.

Lenacapavir works by interfering with the activity of HIV capsid, a protein which protects the virus’ genetic material, playing a key role in its replication.

Gilead’s marketing application included data from a mid-to-late-stage trial, which showed lenacapavir, in combination with other antiretrovirals, helped reduce viral load in people living with HIV who were no longer effectively responding to their current therapy.

Gilead already has several U.S. approved HIV treatments, with Biktarvy being its top selling drug in the category, raking in $8.62 billion in 2021.

Register now for FREE unlimited access to Reuters.com

Reporting by Amruta Khandekar and Leroy Leo in Bengaluru; Editing by Maju Samuel, Sriraj Kalluvila and Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.

Hays County News Online

© 2021 Hays County News Online

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Hays County News Online

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT